Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals

Scientific Reports
Hye Won LeeBeom Kyung Kim

Abstract

Routine nucleos(t)ide analogs (NUCs) have not yet been recommended for patients with immune-tolerant (IT) phase in chronic hepatitis B virus (HBV) infection. We aimed to evaluate prognosis of patients in untreated IT-phase (UIT group), compared to those in immune-active phase who achieved virological response by NUCs according to guidelines (VR group). Between 2006 and 2012, patients in UIT or VR groups were included. Cumulative risks of HCC and liver-related events (LREs) development were assessed. Furthermore, propensity-score was calculated based upon age, gender, diabetes and liver stiffness. UIT group (n = 126) showed younger age, lower proportion of male gender and lower LS than VR group (n = 641). UIT group had similar 10-year cumulative risks of HCC (2.7% vs. 2.9%, p = 0.704) and LRE (4.6% vs. 6.1%, p = 0.903) development, compared to VR group. When we re-defined UIT group by the lower ALT cut-offs, 10-year cumulative risks of HCC and LRE development were 2.9% and 4.8%, respectively. Using propensity-score matching and inverse probability treatment weighting analysis, similar results were reproduced. UIT group consistently had similar prognosis compared to VR group. Therefore, further large-scale prospective studies in ...Continue Reading

References

May 1, 1992·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·H Y HsuD S Chen
Sep 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·D R MilichA McLachlan
Oct 8, 2004·The New England Journal of Medicine·Yun-Fan LiawUNKNOWN Cirrhosis Asian Lamivudine Multicentre Study Group
Jan 5, 2006·JAMA : the Journal of the American Medical Association·Chien-Jen ChenUNKNOWN REVEAL-HBV Study Group
Mar 15, 2006·Gastroenterology·Uchenna H IloejeUNKNOWN Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group
Apr 13, 2007·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Tony AndreaniRaoul Poupon
Jul 14, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Chee-Kin HuiUNKNOWN Hong Kong Liver Fibrosis Study Group
Oct 12, 2007·Journal of Hepatology·Michelle LaiNezam H Afdhal
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Brian J McMahon
Jan 19, 2011·Liver International : Official Journal of the International Association for the Study of the Liver·Yun-Fan Liaw
Feb 15, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kyu Sik JungKwang-Hyub Han
Mar 5, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jordi BruixUNKNOWN American Association for the Study of Liver Diseases
Mar 20, 2012·Journal of Hepatology·UNKNOWN European Association For The Study Of The Liver, UNKNOWN European Organisation For Research And Treatment Of Cancer
Jan 1, 2014·Liver International : Official Journal of the International Association for the Study of the Liver·Laurent Castera
Sep 2, 2014·Cellular & Molecular Immunology·Antonio Bertoletti, Patrick T Kennedy
Nov 27, 2014·Journal of Viral Hepatitis·T-C Tseng, J-H Kao
Nov 14, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Norah A TerraultUNKNOWN American Association for the Study of Liver Diseases
Jan 5, 2016·Liver International : Official Journal of the International Association for the Study of the Liver·Jiannis Vlachogiannakos, George V Papatheodoridis
Apr 6, 2016·Clinical and Molecular Hepatology·UNKNOWN Korean Association for the Study of the Liver
Oct 13, 2016·Clinical and Molecular Hepatology·So Hyun ParkMoon-Gyu Lee
Jan 14, 2017·Clinical and Molecular Hepatology·Chih-Lin Lin, Jia-Horng Kao
Jan 26, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Julien BissonnettePierre-Emmanuel Rautou
Apr 22, 2017·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, UNKNOWN European Association for the Study of the Liver
Sep 26, 2017·Clinical and Molecular Hepatology·Eun Ju ChoYoon Jun Kim
Nov 28, 2017·Gut·Chia-Ming Chu, Yun-Fan Liaw
Jan 23, 2018·Clinical and Molecular Hepatology·Grace Lai-Hung Wong
Feb 7, 2018·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Norah A TerraultJohn B Wong

❮ Previous
Next ❯

Citations

Feb 6, 2020·Journal of Gastroenterology·Hye Won Lee, Henry Lik-Yuen Chan
Dec 9, 2020·European Journal of Internal Medicine·Hye Won LeeSang Hoon Ahn
Sep 19, 2020·European Journal of Gastroenterology & Hepatology·Cristiane V TovoAngelo A de Mattos
May 21, 2020·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Wen-Juei Jeng, Anna S Lok

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Software Mentioned

SAS
SPSS®
IPTW
R

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.